Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS

NCT06436703 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06436703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06436703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
May 23, 2024
Completion date
February 5, 2025
Enrollment
1,202 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human